



Asthma Associates With Human Abdominal Aortic Aneurysm and RuptureSignificance

Citation

Liu, Cong-Lin, Holger Wemmelund, Yi Wang, Mengyang Liao, Jes S. Lindholt, Søren P. Johnsen, Henrik Vestergaard, et al. 2016. "Asthma Associates With Human Abdominal Aortic Aneurysm and RuptureSignificance." *Arteriosclerosis, Thrombosis, and Vascular Biology* 36 (3) (February 11): 570–578. doi:10.1161/atvbaha.115.306497.

Published Version

10.1161/ATVBAHA.115.306497

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:25757695>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Table 2. Preadmission hospitalization and drug use and the risk of rAAA in Denmark (1996-2012, DNRP).

	rAAA cases n (%)	AAA controls [†] n (%)	Crude OR (95% C.I.)	P value	Adjusted OR ^g (95% C.I.)	P value
Hospital diagnosed asthma						
Ever ^a	146 (3.2)	654 (3.0)	1.08 (0.90–1.30)	0.413	1.02 (0.84–1.24)	0.840
Within 360 days of index date ^b	26 (0.6)	79 (0.4)	1.60 (1.03–2.50)	0.038	1.51 (0.94–2.41)	0.082
Within 180 days of index date ^b	22 (0.5)	60 (0.2)	2.12 (1.28–3.51)	0.003	2.06 (1.21–3.53)	0.008
Preadmission drug use						
Bronchodilator use ^c						
Ever ^d	1,012 (22.5)	4,557 (21.0)	1.10 (1.02–1.19)	0.014	1.10 (1.01–1.19)	0.035
Within 360 days of index date ^b	724 (16.1)	2,996 (13.8)	1.21 (1.10–1.32)	<0.001	1.18 (1.07–1.30)	0.001
Within 180 days of index date ^b	644 (14.3)	2,598 (12.0)	1.24 (1.13–1.36)	<0.001	1.20 (1.08–1.32)	0.001
Within 90 days of index date ^b	574 (12.8)	2,121 (9.8)	1.37 (1.24–1.52)	<0.001	1.31 (1.18–1.46)	<0.001
Selective beta-2-adrenergic receptor agonists ^e						
Ever ^d	983 (21.9)	4383 (20.2)	1.12 (1.03-1.21)	0.007	1.11 (1.02-1.21)	0.019
Within 360 days of index date ^b	682 (15.2)	2,800 (12.9)	1.22 (1.11-1.34)	<0.001	1.18 (1.07-1.21)	0.001
Within 180 days of index date ^b	597 (13.1)	2,416 (11.2)	1.23 (1.12-1.36)	<0.001	1.18 (1.06-1.31)	0.002
Within 90 days of index date ^b	525 (11.7)	1,959 (9.0)	1.35 (1.22-1.50)	<0.001	1.28 (1.15-1.44)	<0.001
Anti-cholinergics ^e						
Ever ^d	300 (6.7)	1,177 (5.4)	1.26 (1.10-1.44)	0.001	1.26 (1.09-1.45)	0.002
Within 360 days of index date ^b	214 (4.8)	830 (3.8)	1.28 (1.09-1.49)	0.002	1.24 (1.05-1.46)	0.012
Within 180 days of index date ^b	196 (4.4)	710 (3.3)	1.37 (1.16-1.61)	<0.001	1.31 (1.10-1.56)	0.002
Within 90 days of index date ^b	176 (3.9)	591 (2.7)	1.48 (1.24-1.76)	<0.001	1.42 (1.18-1.71)	<0.001
Inhaled glucocorticoids						
Ever ^d	550 (12.2)	2,397 (11.1)	1.13 (1.02-1.24)	0.019	1.09 (0.98-1.22)	0.097
Within 360 days of index date ^b	317 (7.0)	1,198 (5.5)	1.31 (1.15-1.49)	<0.001	1.23 (1.07-1.41)	0.003
Within 180 days of index date ^b	266 (5.9)	1,012 (4.7)	1.29 (1.12-1.49)	<0.001	1.21 (1.04-1.40)	0.013
Within 90 days of index date ^b	219 (4.9)	731 (3.4)	1.49 (1.28-1.75)	<0.001	1.35 (1.14-1.71)	<0.001
Theophylline						
Ever ^d	165 (3.7)	599 (2.8)	1.34 (1.13-1.60)	0.001	1.24 (1.03-1.49)	0.021
Within 360 days of index date ^b	90 (2.0)	271 (1.3)	1.63 (1.28-2.08)	<0.001	1.41 (1.10-1.82)	0.007
Within 180 days of index date ^b	85 (1.9)	245 (1.1)	1.70 (1.32-2.18)	<0.001	1.46 (1.13-1.90)	0.004
Within 90 days of index date ^b	69 (1.5)	189 (0.9)	1.79 (1.35-2.36)	<0.001	1.48 (1.11-1.97)	0.008

a). Since Jan 1, 1977; b). Patients were among the “Ever” group; c). Bronchodilators with selective beta-2-adrenergic receptor agonists and anti-cholinergics; d). Since Jan 1, 1995; e). Patients prescribed selective beta-2-adrenergic receptor agonists and anti-cholinergics were among the bronchodilator use group; f). Number of case sex- and age-matched AAA patients may be used for more than one category; g). Adjusted for myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, diabetes with or without complications, and moderate to severe renal disease), concomitant drug use (ACE-inhibitors, Ang-II antagonists, aldosterone antagonists, beta-2-adrenergic receptor blocking agents, calcium antagonists, statins, anti-platelet therapy, anti-diabetic therapy, corticosteroids, and NSAIDs), the number of visits to a general practitioner in the year before admission, income, and marital status.
OR, odds ratio; C.I., confidence interval; NSAID, non-steroidal anti-inflammatory drug.